Pharmacogenetics in solid organ transplantation: current status and future directions (Q37218086)

19 August 2017

1 reference

title

Pharmacogenetics in solid organ transplantation: current status and future directions (English)

1 reference

19 August 2017

main subject

organ transplantation

1 reference

Hylke de Jonge

1

1 reference

19 August 2017

Dirk R J Kuypers

series ordinal

2

1 reference

19 August 2017

publication date

1 January 2008

1 reference

19 August 2017

published in

Transplantation Reviews

1 reference

19 August 2017

volume

22

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

6-20

1 reference

Organ transplantation--how much of the promise has been realized?

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Pharmacogenomics--drug disposition, drug targets, and side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Genetics of the variable expression of CYP3A in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Genetic contribution to variable human CYP3A-mediated metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The natural history of chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.002

10.1016/J.TRRE.2007.09.002

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference